Europe Diabetes Care Devices Market Size & Share Report, 2034

Europe Diabetes Care Devices Market - By Product, By End Use - Regional Forecast, 2025 - 2034

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definition

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Data mining sources

1.3.1&nbsp;&nbsp;&nbsp; Country

1.4&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.4.1&nbsp;&nbsp;&nbsp; Base year calculation

1.4.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.6&nbsp;&nbsp;&nbsp; Forecast model

1.7&nbsp;&nbsp;&nbsp; Research assumptions and limitations

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

2.2&nbsp;&nbsp;&nbsp; Key market trends

2.2.1&nbsp;&nbsp;&nbsp; Country trends

2.2.2&nbsp;&nbsp;&nbsp; Product trends

2.2.3&nbsp;&nbsp;&nbsp; End use trends

2.3&nbsp;&nbsp;&nbsp; CXO perspectives: Strategic imperatives

2.3.1&nbsp;&nbsp;&nbsp; Key decision points for industry executives

2.3.2&nbsp;&nbsp;&nbsp; Critical success factors for market players

2.4&nbsp;&nbsp;&nbsp; Future outlook and strategic recommendations

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.1.1&nbsp;&nbsp;&nbsp; Supplier landscape

3.1.2&nbsp;&nbsp;&nbsp; Value addition at each stage

3.1.3&nbsp;&nbsp;&nbsp; Factor affecting the value chain

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Rising prevalence of diabetes and obesity in Europe

3.2.1.2&nbsp;&nbsp;&nbsp; Technological advancements in CGM and smart insulin pens

3.2.1.3&nbsp;&nbsp;&nbsp; Supportive reimbursement policies and insurance coverage

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High cost of advanced devices and limited rural access

3.2.2.2&nbsp;&nbsp;&nbsp; Rigorous regulatory framework

3.2.2.3&nbsp;&nbsp;&nbsp; Data residency and privacy regulations

3.2.3&nbsp;&nbsp;&nbsp; Market opportunities

3.2.3.1&nbsp;&nbsp;&nbsp; Integrated care models combining CGM, insulin delivery, and telehealth

3.2.3.2&nbsp;&nbsp;&nbsp; AI-enabled decision support and closed-loop insulin automation

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Technological advancements

3.5.1&nbsp;&nbsp;&nbsp; Current technological trends

3.5.2&nbsp;&nbsp;&nbsp; Emerging technologies

3.5.2.1&nbsp;&nbsp;&nbsp; Non-Invasive glucose monitoring technologies

3.5.2.2&nbsp;&nbsp;&nbsp; Nanotechnology applications

3.6&nbsp;&nbsp;&nbsp; Diabetes epidemiology and disease burden analysis

3.6.1&nbsp;&nbsp;&nbsp; Regional diabetes prevalence trends

3.6.2&nbsp;&nbsp;&nbsp; Gestational diabetes prevalence

3.6.3&nbsp;&nbsp;&nbsp; Complication rates and healthcare costs

3.7&nbsp;&nbsp;&nbsp; Patent landscape analysis for diabetes device innovations

3.8&nbsp;&nbsp;&nbsp; Clinical trial pipeline assessment for emerging technologies

3.9&nbsp;&nbsp;&nbsp; Supply chain risk analysis for key device components

3.10&nbsp;&nbsp;&nbsp; Patient behavior and technology adoption patterns in diabetes care devices

3.11&nbsp;&nbsp;&nbsp; Reimbursement scenario

3.11.1&nbsp;&nbsp;&nbsp;Coding and reimbursement

3.11.2&nbsp;&nbsp;&nbsp;Reimbursement policies and public healthcare sector insurance coverage for insulin delivery systems

3.12&nbsp;&nbsp;&nbsp; Pricing analysis, 2024

3.13&nbsp;&nbsp;&nbsp; Future market trends

3.14&nbsp;&nbsp;&nbsp; Gap analysis

3.15&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.16&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2024

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.3&nbsp;&nbsp;&nbsp; Company matrix analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Strategy dashboard

4.7&nbsp;&nbsp;&nbsp; Key developments

4.7.1&nbsp;&nbsp;&nbsp; Mergers and acquisitions

4.7.2&nbsp;&nbsp;&nbsp; Partnerships and collaborations

4.7.3&nbsp;&nbsp;&nbsp; New product launches

4.7.4&nbsp;&nbsp;&nbsp; Expansion plans

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Devices

5.2.1&nbsp;&nbsp;&nbsp; Blood glucose monitoring devices

5.2.1.1&nbsp;&nbsp;&nbsp; Self-monitoring blood glucose meters

5.2.1.2&nbsp;&nbsp;&nbsp; Continuous glucose monitors

5.2.2&nbsp;&nbsp;&nbsp; Insulin delivery devices

5.2.2.1&nbsp;&nbsp;&nbsp; Insulin pumps

5.2.2.1.1&nbsp;&nbsp;&nbsp; Tubed pumps

5.2.2.1.2&nbsp;&nbsp;&nbsp; Tubeless pumps

5.2.2.2&nbsp;&nbsp;&nbsp; Pens

5.2.2.2.1&nbsp;&nbsp;&nbsp; Reusable

5.2.2.2.2&nbsp;&nbsp;&nbsp; Disposable

5.2.2.3&nbsp;&nbsp;&nbsp; Other insulin delivery devices

5.3&nbsp;&nbsp;&nbsp; Consumables

5.3.1&nbsp;&nbsp;&nbsp; Testing strips

5.3.2&nbsp;&nbsp;&nbsp; Lancets

5.3.3&nbsp;&nbsp;&nbsp; Pen needles

5.3.3.1&nbsp;&nbsp;&nbsp; Standard

5.3.3.2&nbsp;&nbsp;&nbsp; Safety

5.3.4&nbsp;&nbsp;&nbsp; Syringes

5.3.5&nbsp;&nbsp;&nbsp; Insulin pumps consumables

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Hospital

6.3&nbsp;&nbsp;&nbsp; Ambulatory surgical centers

6.4&nbsp;&nbsp;&nbsp; Diagnostic centers

6.5&nbsp;&nbsp;&nbsp; Homecare

6.6&nbsp;&nbsp;&nbsp; Other end use

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Country, 2021 - 2034 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Europe

7.2.1&nbsp;&nbsp;&nbsp; Germany

7.2.2&nbsp;&nbsp;&nbsp; France

7.2.3&nbsp;&nbsp;&nbsp; UK

7.2.4&nbsp;&nbsp;&nbsp; Italy

7.2.5&nbsp;&nbsp;&nbsp; Spain

7.2.6&nbsp;&nbsp;&nbsp; Netherlands

7.2.7&nbsp;&nbsp;&nbsp; Sweden

7.2.8&nbsp;&nbsp;&nbsp; Belgium

7.2.9&nbsp;&nbsp;&nbsp; Denmark

7.2.10&nbsp;&nbsp;&nbsp;Finland

7.2.11&nbsp;&nbsp;&nbsp;Norway

7.2.12&nbsp;&nbsp;&nbsp;Lithuania

7.2.13&nbsp;&nbsp;&nbsp;Latvia

7.2.14&nbsp;&nbsp;&nbsp;Estonia

7.2.15&nbsp;&nbsp;&nbsp;Russia

7.2.16&nbsp;&nbsp;&nbsp;Poland

7.2.17&nbsp;&nbsp;&nbsp;Switzerland

Chapter 8&nbsp;&nbsp;&nbsp;Company Profiles

8.1&nbsp;&nbsp;&nbsp; Abbott Laboratories

8.2&nbsp;&nbsp;&nbsp; ARKRAY

8.3&nbsp;&nbsp;&nbsp; Ascensia Diabetes Care

8.4&nbsp;&nbsp;&nbsp; B. Braun Melsungen

8.5&nbsp;&nbsp;&nbsp; Becton, Dickinson and Company

8.6&nbsp;&nbsp;&nbsp; Bionime

8.7&nbsp;&nbsp;&nbsp; DarioHealth

8.8&nbsp;&nbsp;&nbsp; Dexcom

8.9&nbsp;&nbsp;&nbsp; Dr. Reddy&rsquo;s Laboratories

8.10&nbsp;&nbsp;&nbsp; Eli Lilly and Company

8.11&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche

8.12&nbsp;&nbsp;&nbsp; Insulet

8.13&nbsp;&nbsp;&nbsp; Medtronic

8.14&nbsp;&nbsp;&nbsp; Nova Biomedical

8.15&nbsp;&nbsp;&nbsp; Novo Nordisk

8.16&nbsp;&nbsp;&nbsp; Sanofi

8.17&nbsp;&nbsp;&nbsp; Ypsomed Holding 
&nbsp;

Europe Diabetes Care Devices Market

Inquiry Before Buying